BioCentury
ARTICLE | Financial News

Affiris raises EUR 10M

June 24, 2016 12:19 AM UTC

Affiris AG (Vienna, Austria) said it raised EUR 10 million ($11.3 million) from FCPB Affi GmbH and existing investors Santo Holding GmbH and MIG Funds.

Affiris expects Phase I data in 1Q17 for AT04A and AT06A, its vaccine candidates targeting PCSK9. The candidates would compete with ALN-PCSsc from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), a subcutaneous formulation of small interfering RNA (siRNA) against PCSK9. Last year, Alnylam said a single dose of the therapy produced durable lowering of LDL-C in a Phase I study (see BioCentury Extra, Aug. 31, 2015). ...